These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26040660)

  • 1. Pharmacokinetics of Colistin Methansulphonate (CMS) and Colistin after CMS Nebulisation in Baboon Monkeys.
    Marchand S; Bouchene S; de Monte M; Guilleminault L; Montharu J; Cabrera M; Grégoire N; Gobin P; Diot P; Couet W; Vecellio L
    Pharm Res; 2015 Oct; 32(10):3403-14. PubMed ID: 26040660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of nebulized colistin methanesulfonate in critically ill patients.
    Boisson M; Grégoire N; Cormier M; Gobin P; Marchand S; Couet W; Mimoz O
    J Antimicrob Chemother; 2017 Sep; 72(9):2607-2612. PubMed ID: 28575278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of diluent volume of colistimethate sodium on aerosol characteristics and pharmacokinetics in ventilator-associated pneumonia caused by MDR bacteria.
    Bihan K; Zahr N; Becquemin MH; Lu X; Bertholon JF; Vezinet C; Arbelot C; Monsel A; Rouby JJ; Langeron O; Lu Q
    J Antimicrob Chemother; 2018 Jun; 73(6):1639-1646. PubMed ID: 29506194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.
    Landersdorfer CB; Nguyen TH; Lieu LT; Nguyen G; Bischof RJ; Meeusen EN; Li J; Nation RL; McIntosh MP
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses.
    Marchand S; Lamarche I; Gobin P; Couet W
    J Antimicrob Chemother; 2010 Aug; 65(8):1753-8. PubMed ID: 20507861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinations of colistin solutions and nebulisers for lung infection management in cystic fibrosis patients.
    Buttini F; Rossi I; Di Cuia M; Rossi A; Colombo G; Elviri L; Sonvico F; Balducci AG
    Int J Pharm; 2016 Apr; 502(1-2):242-8. PubMed ID: 26854429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats.
    Marchand S; Gobin P; Brillault J; Baptista S; Adier C; Olivier JC; Mimoz O; Couet W
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3702-7. PubMed ID: 20547787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients.
    Rottier BL; van Erp CJ; Sluyter TS; Heijerman HG; Frijlink HW; Boer AH
    J Aerosol Med Pulm Drug Deliv; 2009 Sep; 22(3):263-9. PubMed ID: 19466906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.
    Boisson M; Jacobs M; Grégoire N; Gobin P; Marchand S; Couet W; Mimoz O
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7331-9. PubMed ID: 25267660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients.
    Govoni M; Poli G; Acerbi D; Santoro D; Cicirello H; Annoni O; Ružička J
    Pulm Pharmacol Ther; 2013 Apr; 26(2):249-55. PubMed ID: 23232039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of amount and speed of deposition between the PARI LC STAR® jet nebulizer and an investigational eFlow® nebulizer.
    Coates AL; Green M; Leung K; Chan J; Ribeiro N; Ratjen F; Charron M
    J Aerosol Med Pulm Drug Deliv; 2011 Jun; 24(3):157-63. PubMed ID: 21361784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration.
    Yapa SWS; Li J; Patel K; Wilson JW; Dooley MJ; George J; Clark D; Poole S; Williams E; Porter CJ; Nation RL; McIntosh MP
    Antimicrob Agents Chemother; 2014 May; 58(5):2570-9. PubMed ID: 24550334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.
    Grégoire N; Mimoz O; Mégarbane B; Comets E; Chatelier D; Lasocki S; Gauzit R; Balayn D; Gobin P; Marchand S; Couet W
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7324-30. PubMed ID: 25267662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration.
    Karaiskos I; Friberg LE; Galani L; Ioannidis K; Katsouda E; Athanassa Z; Paskalis H; Giamarellou H
    Int J Antimicrob Agents; 2016 Sep; 48(3):337-41. PubMed ID: 27474468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate.
    Li J; Milne RW; Nation RL; Turnidge JD; Smeaton TC; Coulthard K
    J Antimicrob Chemother; 2004 May; 53(5):837-40. PubMed ID: 15044428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
    Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing.
    Jitmuang A; Nation RL; Koomanachai P; Chen G; Lee HJ; Wasuwattakul S; Sritippayawan S; Li J; Thamlikitkul V; Landersdorfer CB
    J Antimicrob Chemother; 2015; 70(6):1804-11. PubMed ID: 25698772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis.
    Jacobs M; Grégoire N; Mégarbane B; Gobin P; Balayn D; Marchand S; Mimoz O; Couet W
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1788-93. PubMed ID: 26729492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary Pharmacokinetics of Colistin following Administration of Dry Powder Aerosols in Rats.
    Lin YW; Zhou QT; Hu Y; Onufrak NJ; Sun S; Wang J; Forrest A; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections.
    Yapa SWS; Li J; Porter CJ; Nation RL; Patel K; McIntosh MP
    Antimicrob Agents Chemother; 2013 Oct; 57(10):5087-95. PubMed ID: 23917323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.